

Jazz Pharmaceuticals plc  
Form 8-K  
March 04, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

March 4, 2013

Date of Report (Date of earliest event reported)

**JAZZ PHARMACEUTICALS PUBLIC LIMITED  
COMPANY**

(Exact name of registrant as specified in its charter)

Edgar Filing: Jazz Pharmaceuticals plc - Form 8-K

**Ireland**  
(State or other jurisdiction  
of incorporation)

**001-33500**  
(Commission

**98-1032470**  
(IRS Employer

File No.)  
**Fourth Floor, Connaught House,**

Identification No.)

**One Burlington Road, Dublin 4, Ireland**

(Address of principal executive offices, including zip code)

**011-353-1-634-7800**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

Jazz Pharmaceuticals plc (the Company) is filing this Current Report on Form 8-K to present the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2012 that give effect to the two transactions consummated during the year ended December 31, 2012 described below in Item 9.01(b).

**Item 9.01. Financial Statements and Exhibits.**

**(b) Pro Forma Financial Information**

The Company completed two transactions during the year ended December 31, 2012 for which pro forma financial information has previously been included in its filings with the Securities and Exchange Commission. On January 18, 2012, Azur Pharma Public Company Limited (Azur) and Jazz Pharmaceuticals, Inc. (JPI) completed a merger transaction (the Azur Merger). For accounting purposes, the Azur Merger was treated as a reverse acquisition of Azur by JPI, which was considered the accounting acquirer, and the financial statements of JPI became the historical financial statements of the Company. On June 12, 2012, the Company completed the acquisition of EUSA Pharma, Inc. (the EUSA Acquisition).

The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2012, giving effect to the Azur Merger and the EUSA Acquisition, and the notes related thereto, are included as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated herein by reference.

**(d) Exhibits**

**Exhibit**

<b>Number</b>	<b>Description</b>
99.1	Unaudited pro forma condensed combined statement of operations for the year ended December 31, 2012.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY

By: /s/ Karen J. Wilson

Name: Karen J. Wilson

Title: Senior Vice President, Finance

(Principal Accounting Officer)

Date: March 4, 2013

EXHIBIT INDEX

<b>Exhibit Number</b>	<b>Description</b>
99.1	Unaudited pro forma condensed combined statement of operations for the year ended December 31, 2012.